Prognosis
Brazil’s Fiocruz Says Vaccine May Be Delayed by Supply Shortage
- To meet original goals, supplies need to arrive within days
- Vaccine’s active pharmaceutical ingredient is stuck in China
This article is for subscribers only.
Brazil’s Fiocruz, which partnered with AstraZeneca/Oxford to produce coronavirus vaccines locally, said it may fail to deliver the shots on schedule next month because of difficulty getting a key ingredient from China.
The Rio de Janeiro-based research institute had planned to have the first million doses of the shots ready the week of Feb. 8. But the vaccine’s active pharmaceutical ingredient -- known locally as IFA -- is stuck in China awaiting approval to ship.